Recent studies demonstrated that reducing ACE2 expression might promote the lung’s inflammatory process and the subsequent cytokine storm in many severe COVID-19 patients (Rodrigues Prestes et al., 2017; Banu et al., 2020; Wang et al., 2020). Here, ACE2 is linked to COVID-19.